Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species

• DOI: 10.1093/jac/dky280
• Publication Date: 2018-06-21T19:09:09Z
• Authors: Nathan P Wiederhold; Jeffrey B Locke; Paul Daruwala; Ken Bartizal
• Keywords: Posaconazole; Azole; Broth microdilution; Echinocandins; Anidulafungin

Rezafungin is an investigational echinocandin under development for the treatment and prevention of invasive fungal infections, with a long half-life in humans (∼130 h) potent vitro activity against Aspergillus spp. Our objective was to further evaluate its fumigatus isolates, including azole-resistant isolates cryptic spp.Clinical were used, 15 WT 31 A. fumigatus, 11 lentulus, 5 each thermomutatus udagawae calidoustus. Minimum effective concentrations (MECs) MICs rezafungin, caspofungin, micafungin, posaconazole voriconazole determined by CLSI M38-A2 broth microdilution. Differences geometric mean (GM) MEC/MIC values assessed significance ANOVA.Rezafungin GM MECs 0.024 0.043 mg/L respectively. also active species, lentulus (0.016 mg/L), calidoustus (0.044 (MEC range ≤0.015-0.25 mg/L) (≤0.015-0.03 mg/L). This similar that caspofungin micafungin exception calidoustus, which rezafungin more than (GM MEC 0.044 versus 0.468 mg/L; P < 0.0001).Rezafungin demonstrated spp., species elevated MICs. Additional studies are warranted determine whether translates into vivo efficacy infections caused resistant isolates.